Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

or parkinsonism. Both of these scales documented minimal symptoms at baseline and there was no worsening during the six weeks of treatment. Clinical hematology, chemistry and ECG monitoring indicated no emergent safety signals.

There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

Next Steps for NBI-98854Data from the Kinect 2 study will be integrated with the Kinect study data to inform the ultimate design of the next study, Kinect 3. The Company will work with its consultants and scientific advisors to expand and refine the pharmacokinetic/pharmacodynamic models as well as to complete the remaining safety and efficacy analyses from both Kinect and Kinect 2. These data will form the basis for an End of Phase II briefing package along with the proposed Phase III protocol.

Kinect 2 Study DesignThe Kinect 2 Study was a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 100 subject study assessed once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects received placebo and half received NBI-98854. The NBI-98854 dosing regimen began with a once-daily dose of 25 mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients were titrated to a once-daily 50 mg dose, or continued on the once-daily 25 mg dose for the following two-week period. At the completion of the second two weeks of treatment another efficacy and safety assessment was performed and patients were eligible to be titrated to a once-daily 75 mg, 50 mg or 25 mg dose for the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014  PneumRx, Inc. ( www.pneumrx.com ), a ... completion of enrollment in their RENEW Study, nearly 3 ... the FDA-approved IDE pivotal trial for the PneumRx RePneu ... It was anticipated that the study, which began enrolling ... until the end of 2014 to enroll 315 patients.  ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics announced ... the ability to collect human data at 30X depth, sufficient ... chip.  This new capability was established and demonstrated for the ... Irys TM System and will be rolled out ... BioNano will be showcasing this advancement at the American ...
Breaking Medicine Technology:PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... care and gastroenterology markets, today announced fourth quarter and full ... For the three months ended December 31, 2010, net revenue ... corresponding period in 2009. This quarterly revenue growth was largely ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... immediately. "I am pleased to have someone of ... Mark Guinan, Senior Vice President and Chief Financial Officer of ... will contribute to the solid financial leadership of our company ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... ... Unresponsive to Conventional Medical Treatments. , ... Boca Raton, FL (PRWEB) July 2, 2010 -- Amy, a 55 ... Under traditional drug treatment, which included five daily pills and injections, Amy,s condition only ...
... ... LA-540, an aspirator and liposuction system that is dependable and affordably-priced. , ... Louisville, KY (Vocus) July 2, ... DRE LA-540 , an affordable aspirator and liposuction system that features two positive ...
... ... It, Personal Notes, and the new book, Write the Right Words, answers the question of what ... ... I write?"--when a friend,s beloved pet dies; a favorite aunt wins that coveted prize; or a ...
... are up to twice as likely as other races ... nearly every common cancer type, the largest differences occur ... that black patients are not getting needed lifesaving treatments, ... of Michigan Comprehensive Cancer Center. Five-year survival rates ...
... ... its new upper extremity range, bebionic. Launched at the ISPO World congress in May, the ... approximately 9,000 Euros, or $11,000 USD. , ... (PRWeb UK) July 1, 2010 -- RSLSteeper have announced the pricing for the ...
... , THURSDAY, July 1 (HealthDay News) -- Scientists have grouped ... 77 percent accuracy whether or not a person will live ... probably could have predicted life span with even greater accuracy ... said Dr. Robert Marion, chief of genetics and development medicine ...
Cached Medicine News:Health News:New Approach to Rheumatoid Arthritis 2Health News:New Approach to Rheumatoid Arthritis 3Health News:DRE Introduces Economically-Priced Liposuction System 2Health News:DRE Introduces Economically-Priced Liposuction System 3Health News:Write the Right Words Answers What-to-Write Questions 2Health News:Why are blacks more likely to die from cancer diagnosis? 2Health News:RSLSteeper announces pricing for new bionic hand 2Health News:Scientists Spot Gene Variants That Predict Longevity 2Health News:Scientists Spot Gene Variants That Predict Longevity 3
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... Spinal Fixation System is ... that provides an innovative ... It combines technical advances ... with a design philosophy ...
The CD Horizon Legacy Spinal System is part of the CD Horizon Spinal System designed for use in small stature patients. The posterior implants (hook and screws) are designed to fit patients in the ra...
... Spine System Evolution offers the latest technology ... of spinal pathologies including degenerative lumbar spine, ... is also intended for the treaent of ... the L5-S1 vertebra. Levels of pedicle screw ...
Medicine Products: